Pharmaceuticals · Pharmaceuticals: Major · NSE: VIYASH · data 2026-10-30
Viyash Scientific Limited
In plain words
Price: 26.7% below its 52-week high of ₹298.
Delivery: 47.2% of traded shares were kept for delivery over the last 10 sessions, against 51.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,149 cr |
| Net profit (last 12 months) | ₹171 cr |
| Sales growth, 3 years (yearly) | 34.1% |
| Profit growth, 3 years (yearly) | — |
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 48.5% over the last 20 sessions vs 49.3% in the 40 before (0.98x); shares delivered per day 0.38x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Viyash Scientific Limited debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Viyash Scientific Limited's P/E ratio?
About 53.4, based on the last 12 months' earnings and a price of ₹218.39 (data 2026-10-30).
What is the 52-week high and low of Viyash Scientific Limited?
The 52-week high is ₹298 and the 52-week low is ₹178.13.
Similar companies
Strides Pharma Science Ltd (STAR) · Blue Jet Healthcare Limited (BLUEJET) · Procter & Gamble Health Ltd. (PGHL) · Aarti Pharmalabs Limited (AARTIPHARM) · Symbiotec Pharmalab Limited (SYMBIOTEC)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VIYASH in NSE Scanner →